Catharina Korsukewitz

Multiple sclerosis is an immune-mediated disease of the central nervous system and a leading cause of neurological disability. Considerable progress in imaging techniques and fluid biomarkers have enhanced our understanding of MS, improving diagnostic, prognostic, and treatment monitoring tools. However, understanding the different clinical manifestations, timely diagnosis and treatment success remains a critical unmet need.

Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains about whether immunotherapies increase the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or increase the risk of severe disease and death upon infection. National and international societies have developed guidelines and statements, but consensus does not exist in several areas.